Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.
Cytokine
Immunotherapy
Melanoma
Steroid
Toxicity
irAE
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
15
09
2020
accepted:
06
01
2021
pubmed:
23
1
2021
medline:
27
7
2021
entrez:
22
1
2021
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) often cause immune-related adverse events (irAEs), most of which are treated with corticosteroids despite evidence suggesting that corticosteroids may blunt antitumor efficacy. We sought to identify cytokine changes that correlate with irAEs and study the impact of corticosteroid treatment on cytokine levels. We analyzed expression of 34 cytokines in 52 melanoma patients who developed irAEs during therapy with ICIs. Luminex serum assay was performed at baseline, 1, 2, and 3 months after starting ICI. Baseline cytokine levels and longitudinal log There were no differences in baseline cytokine levels between patients who developed grade 1-2 irAEs (N = 28) vs. grade 3-4 irAEs (N = 24). Dermatitis patients (N = 8) had significantly higher baseline Ang-1 (p = 0.006) and CD40L (p = 0.005). Pneumonitis patients (N = 4) had significantly higher baseline IL-17 (p = 0.009). Colitis patients (N = 8) had a trend toward decreased GCSF (p = 0.08). Through Spearman's correlation analysis, patients who developed irAEs without receiving corticosteroids (N = 23) exhibited harmonization of cytokine fold-change, with 0/276 pairwise comparisons demonstrating significant divergence. In contrast, corticosteroid treatment in patients with irAEs (N = 15) altered fold-change to a discordant pattern (42/276 diverged, 15.2%). This discordant cytokine pattern in patients receiving corticosteroids is similar to the cytokine pattern in patients who did not develop irAEs (N = 8) during the longitudinal profiling period (41/276, 14.9%). Baseline levels of certain cytokines correlate with specific irAEs in melanoma patients receiving ICIs. irAEs drive a concordant pattern of cytokine fold-change, which is disrupted by corticosteroid treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint inhibitors (ICIs) often cause immune-related adverse events (irAEs), most of which are treated with corticosteroids despite evidence suggesting that corticosteroids may blunt antitumor efficacy. We sought to identify cytokine changes that correlate with irAEs and study the impact of corticosteroid treatment on cytokine levels.
METHODS
METHODS
We analyzed expression of 34 cytokines in 52 melanoma patients who developed irAEs during therapy with ICIs. Luminex serum assay was performed at baseline, 1, 2, and 3 months after starting ICI. Baseline cytokine levels and longitudinal log
RESULTS
RESULTS
There were no differences in baseline cytokine levels between patients who developed grade 1-2 irAEs (N = 28) vs. grade 3-4 irAEs (N = 24). Dermatitis patients (N = 8) had significantly higher baseline Ang-1 (p = 0.006) and CD40L (p = 0.005). Pneumonitis patients (N = 4) had significantly higher baseline IL-17 (p = 0.009). Colitis patients (N = 8) had a trend toward decreased GCSF (p = 0.08). Through Spearman's correlation analysis, patients who developed irAEs without receiving corticosteroids (N = 23) exhibited harmonization of cytokine fold-change, with 0/276 pairwise comparisons demonstrating significant divergence. In contrast, corticosteroid treatment in patients with irAEs (N = 15) altered fold-change to a discordant pattern (42/276 diverged, 15.2%). This discordant cytokine pattern in patients receiving corticosteroids is similar to the cytokine pattern in patients who did not develop irAEs (N = 8) during the longitudinal profiling period (41/276, 14.9%).
CONCLUSIONS
CONCLUSIONS
Baseline levels of certain cytokines correlate with specific irAEs in melanoma patients receiving ICIs. irAEs drive a concordant pattern of cytokine fold-change, which is disrupted by corticosteroid treatment.
Identifiants
pubmed: 33481042
doi: 10.1007/s00262-021-02855-1
pii: 10.1007/s00262-021-02855-1
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Cytokines
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2209-2221Subventions
Organisme : Parker Institute for Cancer Immunotherapy
ID : 5812101
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
Références
West HJ (2015) Immune checkpoint inhibitors. JAMA Oncol 1(1):115–115
doi: 10.1001/jamaoncol.2015.0137
Eun Y, Kim IY, Sun J-M et al (2019) Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep 9(1):14039. https://doi.org/10.1038/s41598-019-50574-6
doi: 10.1038/s41598-019-50574-6
pubmed: 31575933
pmcid: 6773778
Abdel-Rahman O, Eltobgy M, Oweira H, Giryes A, Tekbas A, Decker M (2017) Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review. Immunotherapy 9(14):1175–1183. https://doi.org/10.2217/imt-2017-0108
doi: 10.2217/imt-2017-0108
pubmed: 29067884
Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol: Off J Am Soc Clin Oncol 30(21):2691–2697. https://doi.org/10.1200/JCO.2012.41.6750
doi: 10.1200/JCO.2012.41.6750
Rahma O, Ott P (2018) General principles of immune-related toxicities. In: Marc Ernstoff IP, Robert Caroline, Diab Adi, Hersey Peter (eds) SITC’s guide to managing immunotherapy toxicity. Society for Immunotherapy of Cancer, USA
Khan S, Khan SA, Luo X et al (2019) Immune dysregulation in cancer patients developing immune-related adverse events. Br J Cancer 120(1):63–68. https://doi.org/10.1038/s41416-018-0155-1
doi: 10.1038/s41416-018-0155-1
pubmed: 30377338
Faje AT, Lawrence D, Flaherty K et al (2018) High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124(18):3706–3714. https://doi.org/10.1002/cncr.31629
doi: 10.1002/cncr.31629
pubmed: 29975414
Arbour KC, Mezquita L, Long N et al (2018) Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer. J Clin Oncol 36(28):2872–2878. https://doi.org/10.1200/jco.2018.79.0006
doi: 10.1200/jco.2018.79.0006
pubmed: 30125216
Das S, Johnson DB (2019) Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 7(1):306–306. https://doi.org/10.1186/s40425-019-0805-8
doi: 10.1186/s40425-019-0805-8
pubmed: 31730012
pmcid: 6858629
Scott SC, Pennell NA (2018) Early use of systemic corticosteroids in patients with advanced nsclc treated with nivolumab. J Thorac Oncol 13(11):1771–1775. https://doi.org/10.1016/j.jtho.2018.06.004
doi: 10.1016/j.jtho.2018.06.004
pubmed: 29935305
Fucà G, Galli G, Poggi M et al (2019) Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open 4(1):e000457–e000457. https://doi.org/10.1136/esmoopen-2018-000457
doi: 10.1136/esmoopen-2018-000457
pubmed: 30964126
pmcid: 6435242
Esfahani K, Elkrief A, Calabrese C et al (2020) Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. https://doi.org/10.1038/s41571-020-0352-8
doi: 10.1038/s41571-020-0352-8
pubmed: 32546734
Common terminology criteria for adverse events (ctcae) v5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf
Tarhini AA, Zahoor H, Lin Y et al (2015) Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer 3:39. https://doi.org/10.1186/s40425-015-0081-1
doi: 10.1186/s40425-015-0081-1
pubmed: 26380086
pmcid: 4570556
O’Connor JM, Fessele KL, Steiner J et al (2018) Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials. JAMA Oncol 4(8):e180798–e180798. https://doi.org/10.1001/jamaoncol.2018.0798
doi: 10.1001/jamaoncol.2018.0798
pubmed: 29800974
pmcid: 6143052
Haslam A, Prasad V (2019) Estimation of the percentage of us patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2(5):e192535. https://doi.org/10.1001/jamanetworkopen.2019.2535
doi: 10.1001/jamanetworkopen.2019.2535
pubmed: 31050774
pmcid: 6503493
Herbst RS, Soria J-C, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567. https://doi.org/10.1038/nature14011
doi: 10.1038/nature14011
pubmed: 25428504
pmcid: 4836193
Yamazaki N, Kiyohara Y, Uhara H et al (2017) Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. Cancer Sci 108(5):1022–1031. https://doi.org/10.1111/cas.13226
doi: 10.1111/cas.13226
pubmed: 28266140
pmcid: 5448619
Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA (2018) Cytokines, chemokines, and other biomarkers of response for checkpoint inhibitor therapy in skin cancer. Front Med (Lausanne) 5:351. https://doi.org/10.3389/fmed.2018.00351
doi: 10.3389/fmed.2018.00351
Head L, Gorden N, Gulick RV et al (2019) Biomarkers to predict immune-related adverse events with checkpoint inhibitors. J Clin Oncol 37:131–131. https://doi.org/10.1200/JCO.2019.37.8_suppl.131
doi: 10.1200/JCO.2019.37.8_suppl.131
Valpione S, Pasquali S, Campana LG et al (2018) Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. J Transl Med 16(1):94. https://doi.org/10.1186/s12967-018-1467-x
doi: 10.1186/s12967-018-1467-x
pubmed: 29642948
pmcid: 5896157
Lim SY, Lee JH, Gide TN et al (2019) Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1–based immunotherapy. Clin Cancer Res 25(5):1557–1563. https://doi.org/10.1158/1078-0432.ccr-18-2795
doi: 10.1158/1078-0432.ccr-18-2795
pubmed: 30409824
Kurimoto C, Inaba H, Ariyasu H et al (2020) Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci 111(5):1468–1477. https://doi.org/10.1111/cas.14363
doi: 10.1111/cas.14363
pubmed: 32086984
pmcid: 7226278
Tanaka R, Okiyama N, Okune M et al (2017) Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity. J Dermatol Sci 86(1):71–73. https://doi.org/10.1016/j.jdermsci.2016.12.019
doi: 10.1016/j.jdermsci.2016.12.019
pubmed: 28069323
Phillips GS, Wu J, Hellmann MD et al (2019) Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol 37(30):2746–2758. https://doi.org/10.1200/jco.18.02141
doi: 10.1200/jco.18.02141
pubmed: 31216228
pmcid: 7001790
Xing P, Zhang F, Wang G et al (2019) Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J ImmunoTher Cancer. 7(1):341. https://doi.org/10.1186/s40425-019-0779-6
doi: 10.1186/s40425-019-0779-6
pubmed: 31801636
pmcid: 6894272
Goldinger SM, Stieger P, Meier B et al (2016) Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res 22(16):4023–4029. https://doi.org/10.1158/1078-0432.ccr-15-2872
doi: 10.1158/1078-0432.ccr-15-2872
pubmed: 26957557
Kuroda K, Sapadin A, Shoji T, Fleischmajer R, Lebwohl M (2001) Altered expression of angiopoietins and tie2 endothelium receptor in psoriasis. J Investig Dermatol 116(5):713–720. https://doi.org/10.1046/j.1523-1747.2001.01316.x
doi: 10.1046/j.1523-1747.2001.01316.x
pubmed: 11348459
Chen L, Marble DJ, Agha R et al (2008) The progression of inflammation parallels the dermal angiogenesis in a keratin 14 IL-4-transgenic model of atopic dermatitis. Microcirculation 15(1):49–64. https://doi.org/10.1080/10739680701418416
doi: 10.1080/10739680701418416
pubmed: 17952801
Klein D (2018) The Tumor vascular endothelium as decision maker in cancer therapy. Front Oncol 8:367–367. https://doi.org/10.3389/fonc.2018.00367
doi: 10.3389/fonc.2018.00367
pubmed: 30250827
pmcid: 6139307
Schoenberger SP, Toes REM, van der Voort EIH, Offringa R, Melief CJM (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions. Nature 393(6684):480–483. https://doi.org/10.1038/31002
doi: 10.1038/31002
pubmed: 9624005
pmcid: 9624005
Mehling A, Loser K, Varga G et al (2001) Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J Exp Med 194(5):615–628. https://doi.org/10.1084/jem.194.5.615
doi: 10.1084/jem.194.5.615
pubmed: 11535630
pmcid: 2195942
Ohta Y, Hamada Y (2004) In situ expression of CD40 and CD40 ligand in psoriasis. Dermatology 209(1):21–28. https://doi.org/10.1159/000078582
doi: 10.1159/000078582
pubmed: 15237263
Molinero LL, Gruber M, Leoni J, Woscoff A, Zwirner NW (2003) Up-regulated expression of MICA and proinflammatory cytokines in skin biopsies from patients with seborrhoeic dermatitis. Clin Immunol 106(1):50–54. https://doi.org/10.1016/s1521-6616(03)00003-2
doi: 10.1016/s1521-6616(03)00003-2
pubmed: 12584051
Chong S, Lan H, Zeng K, Zhao X (2016) Serum fractalkine (CX3CL1) concentration correlates with clinical severity in pediatric atopic dermatitis patients. Ann Clin Lab Sci 46(2):168–173
pubmed: 27098623
Staumont-Sallé D, Fleury S, Lazzari A et al (2014) CX
doi: 10.1084/jem.20121350
pubmed: 24821910
pmcid: 4042636
Bae O-N, Noh M, Chun Y-J, Jeong TC (2015) Keratinocytic vascular endothelial growth factor as a novel biomarker for pathological skin condition. Biomol Therapeutics 23(1):12–18. https://doi.org/10.4062/biomolther.2014.102
doi: 10.4062/biomolther.2014.102
Delaunay M, Prévot G, Collot S, Guilleminault L, Didier A, Mazières J (2019) Management of pulmonary toxicity associated with immune checkpoint inhibitors. Eur Respir Rev 28(154):190012. https://doi.org/10.1183/16000617.0012-2019
doi: 10.1183/16000617.0012-2019
pubmed: 31694838
Suresh K, Voong KR, Shankar B et al (2018) Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol 13(12):1930–1939. https://doi.org/10.1016/j.jtho.2018.08.2035
doi: 10.1016/j.jtho.2018.08.2035
pubmed: 30267842
Naidoo J, Cottrell TR, Lipson EJ et al (2020) Chronic immune checkpoint inhibitor pneumonitis. J Immunother Cancer 8(1):e000840. https://doi.org/10.1136/jitc-2020-000840
doi: 10.1136/jitc-2020-000840
pubmed: 32554618
pmcid: 7304886
Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721–1728. https://doi.org/10.1001/jamaoncol.2018.3923
doi: 10.1001/jamaoncol.2018.3923
pubmed: 30242316
pmcid: 6440712
Suresh K, Naidoo J, Zhong Q et al (2019) The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. J Clin Investig 129(10):4305–4315. https://doi.org/10.1172/JCI128654
doi: 10.1172/JCI128654
pubmed: 31310589
pmcid: 6763233
Schoenfeld JD, Nishino M, Severgnini M, Manos M, Mak RH, Hodi FS (2019) Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J ImmunoTher Cancer 7(1):112. https://doi.org/10.1186/s40425-019-0583-3
doi: 10.1186/s40425-019-0583-3
pubmed: 31014385
pmcid: 6480873
Gurczynski SJ, Moore BB (2018) IL-17 in the lung: the good, the bad, and the ugly. Am J Physiol Lung Cell Mol Physiol 314(1):L6–L16. https://doi.org/10.1152/ajplung.00344.2017
doi: 10.1152/ajplung.00344.2017
pubmed: 28860146
Fong DJ, Hogaboam CM, Matsuno Y, Akira S, Uematsu S, Joshi AD (2010) Toll-like receptor 6 drives interleukin-17A expression during experimental hypersensitivity pneumonitis. Immunology 130(1):125–136. https://doi.org/10.1111/j.1365-2567.2009.03219.x
doi: 10.1111/j.1365-2567.2009.03219.x
pubmed: 20070409
pmcid: 2855800
Kim S, Shannon V, Sheshadri A et al (2018) TH1/17 hybrid CD4+ cells in bronchial alveolar lavage fluid from leukemia patients with checkpoint inhibitor-induced pneumonitis. J Clini Oncol 36:204–204. https://doi.org/10.1200/JCO.2018.36.5_suppl.204
doi: 10.1200/JCO.2018.36.5_suppl.204
Wang YN, Lou DF, Li DY et al (2020) Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. Oncol Lett 20(1):611–622. https://doi.org/10.3892/ol.2020.11618
doi: 10.3892/ol.2020.11618
pubmed: 32565986
pmcid: 7285943
Marthey L, Mateus C, Mussini C et al (2016) Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 10(4):395–401. https://doi.org/10.1093/ecco-jcc/jjv227
doi: 10.1093/ecco-jcc/jjv227
pubmed: 26783344
pmcid: 4946758
Abu-Sbeih H, Faleck DM, Ricciuti B et al (2020) Immune checkpoint inhibitor therapy in patients With preexisting inflammatory bowel disease. J Clini Oncol 38(6):576–583. https://doi.org/10.1200/jco.19.01674
doi: 10.1200/jco.19.01674
Tyan K, Grover S, Dougan M et al (2020) Association of vitamin D intake with decreased risk of immune checkpoint inhibitor-induced colitis. J Clini Oncol 38:89–89. https://doi.org/10.1200/JCO.2020.38.5_suppl.89
doi: 10.1200/JCO.2020.38.5_suppl.89
Grover S, Dougan M, Tyan K et al (2020) Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer 126(16):3758–3767. https://doi.org/10.1002/cncr.32966
doi: 10.1002/cncr.32966
pubmed: 32567084
Yoshino K, Nakayama T, Ito A, Sato E, Kitano S (2019) Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. BMC Cancer 19(1):1019. https://doi.org/10.1186/s12885-019-6138-7
doi: 10.1186/s12885-019-6138-7
pubmed: 31664934
pmcid: 6819390
Meshkibaf S, Martins AJ, Henry GT, Kim SO (2016) Protective role of G-CSF in dextran sulfate sodium-induced acute colitis through generating gut-homing macrophages. Cytokine 78:69–78. https://doi.org/10.1016/j.cyto.2015.11.025
doi: 10.1016/j.cyto.2015.11.025
pubmed: 26687628
Barahona-Garrido J, Yamamoto-Furusho JK (2008) New treatment options in the management of IBD - focus on colony stimulating factors. Biologics Targets Ther 2(3):501–504. https://doi.org/10.2147/btt.s3543
doi: 10.2147/btt.s3543
Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J ImmunoTher Cancer 5(1):95. https://doi.org/10.1186/s40425-017-0300-z
doi: 10.1186/s40425-017-0300-z
pubmed: 29162153
pmcid: 5697162
Haratani K, Hayashi H, Chiba Y et al (2018) Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer. JAMA Oncol 4(3):374–378. https://doi.org/10.1001/jamaoncol.2017.2925
doi: 10.1001/jamaoncol.2017.2925
pubmed: 28975219
Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886–894. https://doi.org/10.1158/1078-0432.ccr-15-1136
doi: 10.1158/1078-0432.ccr-15-1136
pubmed: 26446948